4-叔丁氧羰基氨基-2-溴吡啶 | 433711-95-6

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-叔丁氧羰基氨基-2-溴吡啶
• 中文别名: 2-溴吡啶-4-氨甲酸叔丁酯；4-(Boc-氨基)-2-溴吡啶；4-BOC氨基-2-溴吡啶
• 英文名称: tert-butyl (2-bromopyridin-4-yl)carbamate
• 英文别名: 4-(Boc-amino)-2-bromopyridine；tert-butyl N-(2-bromopyridin-4-yl)carbamate
• CAS: 433711-95-6
• 化学式: C₁₀H₁₃BrN₂O₂
• 分子量: 273.129
• InChiKey: DCYAZECOQNZWBD-UHFFFAOYSA-N

物化性质

• 沸点：
  299.3±25.0 °C(Predicted)
• 密度：
  1.453±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R22
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P280,P305+P351+P338

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(Boc-amino)-2-bromopyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(Boc-amino)-2-bromopyridine
CAS number: 433711-95-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H13BrN2O2
Molecular weight: 273.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-叔丁氧羰基氨基-2-溴吡啶 在 盐酸 、 正丁基锂 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 4.0h， 生成 4-(4-aminopyridin-2-yl)tetrahydro-2H-pyran-4-ol
  参考文献：
  名称：

  4-（吡啶-4-氧基）-3-（3,3-二氟环丁基）-吡唑衍生物的合成和生物学评估，该衍生物为新型有效的转化生长因子-β1型受体抑制剂。

  摘要：

  抑制转化生长因子β（TGF-β）1型受体（ALK5）提供了一种治疗纤维化疾病和恶性肿瘤的可行方法。在这项研究中，我们设计并合成了一系列新的4-（吡啶-4-氧基）-3-（3,3-二氟环丁基）-吡唑衍生物，并作为TGF-β1型受体抑制剂进行了生物学评估。最有效的化合物15r抑制ALK5酶和NIH3T3细胞的活力，IC50值分别为44和42.5 nM。与LY-3200882相比，化合物15r还具有更好的口服血浆暴露和出色的生物利用度，并且在CT26异种移植小鼠模型中体内抑制了65.7％的肿瘤生长。

  DOI：

  10.1016/j.ejmech.2020.112354
• 作为产物：
  描述：

  2-溴-4-硝基吡啶 、 二碳酸二叔丁酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 4-叔丁氧羰基氨基-2-溴吡啶
  参考文献：
  名称：

  TGF-βR1抑制剂及其应用

  摘要：

  本发明属于医药化学领域，涉及一类作为TGF‑βR1抑制剂的化合物及其应用，具体地，本发明提供式I所示的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药，它们的制备方法以及含有这些化合物的药物组合物和这些化合物或组合物用于治疗和/或预防TGF‑βR1相关疾病，例如癌症、组织增生类疾病、纤维化和炎性疾病等类疾病的用途。本发明的化合物对TGF‑βR1激酶表现出了显著的抑制活性，非常有希望成为TGF‑βR1相关疾病的治疗剂。

  公开号：

  CN111196804A

文献信息

• [EN] CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF<br/>[FR] INHIBITEURS DE CAFÉINE DE MTHFD2 ET LEURS UTILISATIONS
  申请人：RAZE THERAPEUTICS INC

  公开号：WO2017106352A1

  公开（公告）日：2017-06-22

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• [EN] PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5<br/>[FR] INHIBITEURS D'ALK 5 À BASE DE PYRAZOLO[4,3-B]PYRIDINE-7-AMINE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2011146287A1

  公开（公告）日：2011-11-24

  The present invention provides ALK5 inhibitors of the formula (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, methods of making the compounds and intermediates thereof; and methods of using the compounds.

  本发明提供了式(I)的ALK5抑制剂，其中变量如本文所定义。还提供了药物组合物、制备化合物及其中间体的方法；以及使用这些化合物的方法。
• Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1
  申请人：Schering Corporation

  公开号：US20030119847A1

  公开（公告）日：2003-06-26

  Novel compounds of the formula 1 wherein R is optionally substituted heteroaryl or 2 R 1 is H or C 1 —C 6 alkyl; and R 2 and R 3 are —CH 3 , —OCH 3 or halo; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions therefore, and the use of said compounds in the treatment of pain, anxiety, cough, asthma, depression and alcohol abuse are disclosed.

  公开了具有以下结构的新化合物： 其中R是可选择取代的杂环烷基或2R1为H或C1—C6烷基；以及R2和R3为—CH3，—O 或卤素；或其药学上可接受的盐或溶剂，以及相应的药物组合物，以及所述化合物在治疗疼痛、焦虑、咳嗽、哮喘、抑郁症和酒精滥用中的用途。
• Syntheses of [¹¹C]2- and [¹¹C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for demyelinating diseases
  作者：Karla M. Ramos-Torres、Yu-Peng Zhou、Bo Yeun Yang、Nicolas J. Guehl、Moon Sung-Hyun、Sanjay Telu、Marc D. Normandin、Victor W. Pike、Pedro Brugarolas

  DOI：10.1039/d0md00190b

  日期：——

  Trifluoromethyl groups are of great interest in PET radiopharmaceuticals. Radiolabelled 4-aminopyridine (4AP) derivatives have been proposed for imaging demyelinating diseases. Here, we describe methods for producing 11C-trifluoromethylated derivatives of 4AP and present early imaging results with [11C]3-trifluoromethyl-4AP in a rhesus macaque. This study shows the utility of [11C]CuCF3 for labelling

  三氟甲基在 PET 放射性药物中很受关注。已提议使用放射性标记的 4-氨基吡啶 (4AP) 衍生物对脱髓鞘疾病进行成像。在这里，我们描述了生产4AP 的11 C-三氟甲基化衍生物的方法，并展示了在恒河猴中使用 [ 11 C]3-三氟甲基-4AP 的早期成像结果。该研究显示了 [ 11 C]CuCF 3用于标记吡啶的效用，并为 [ 11 C]3-三氟甲基-4AP 作为 PET 放射性配体的潜在用途提供了初步证据。
• Pyridylphosphinate metal complexes: synthesis, structural characterisation and biological activity
  作者：Jasmine M. Cross、Natalie Gallagher、Jason H. Gill、Mohit Jain、Archibald W. McNeillis、Kimberly L. Rockley、Fiona H. Tscherny、Natasha J. Wirszycz、Dmitry S. Yufit、James W. Walton

  DOI：10.1039/c6dt01264g

  日期：——

  time, a series of 25 pseudo-octahedral pyridylphosphinate metal complexes (Ru, Os, Rh, Ir) has been synthesised and assessed in biological systems. Each metal complex incorporates a pyridylphosphinate ligand, a monodentate halide and a capping η6-bound aromatic ligand. Solid- and solution-state analyses of two complexes reveal a structural preference for one of a possible two diastereomers. The metal

  首次合成了25种伪八面体吡啶基次膦酸酯金属配合物（Ru，Os，Rh，Ir），并在生物系统中进行了评估。每个金属络合物结合有pyridylphosphinate配体，单齿卤化物和η封盖6结合的芳族配体。两种配合物的固相和溶液状态分析表明，结构上偏爱可能的两种非对映异构体之一。金属氯化物在D 2 O中迅速水解，在水和氯化物加合物之间形成1：1的平衡比。水合加合物的p K a取决于吡啶基取代基和金属，但对次膦酸酯R'基的依赖性很小。体外毒性对抗非小细胞肺癌H460细胞，最有效的复合物的IC 50值约为50μM。与所选氨基酸和核碱基的结合研究为该系列中观察到的毒性变化提供了理论依据。最后，对螯合氨基酸L- His取代次膦酸盐O-金属键的能力的研究表明，次膦酸盐复合物有可能在细胞内环境中被激活为前药。